



SCOTT GOTTLIEB, M.D.

Scott Gottlieb, MD is a practicing physician and Resident Fellow at the American Enterprise Institute. A leading expert in health policy, Dr. Gottlieb's work focuses on providing insights into the economic and technological forces driving the transformation of healthcare.

From 2005-2007, Dr. Gottlieb served as FDA Deputy Commissioner for Medical and Scientific Affairs and before that, from 2003-2004, as a senior advisor to the FDA Commissioner and as the FDA's Director of Medical Policy Development. He left FDA in the spring of 2004 to work on implementation of the new Medicare Drug Benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency's coverage process, particularly related to new medical technologies.

Dr. Gottlieb is the author of more than 300 articles that have appeared in leading medical journals as well as The Wall Street Journal, The New York Times, USA Today and Forbes Magazine. Dr. Gottlieb has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on the cable financial news channel CNBC. He is an invited contributor to POLITICO.com, an editorial board member of the journal Value Based Cancer Care, the Food and Drug Law Institute's Policy Forum, and is a member of the board of advisers of Cancer Commons. Dr. Gottlieb also serves as an advisor to the National Comprehensive Cancer Network, and a member of NCCN's working groups. Dr. Gottlieb served as a Healthcare Adviser to the Mitt Romney for President Campaign in 2012.

Dr. Gottlieb is currently a Venture Partner at the venture capital firm New Enterprise Associates. Previously Dr. Gottlieb worked as a healthcare analyst for the investment bank Alex Brown & Sons and a Partner to Arcoda Capital, a healthcare investment fund. He was author of the Forbes-Gottlieb Medical Technology Letter published by Forbes Magazine and the Gilder Biotech Report; published by futurist George Gilder. A noted authority on pathways to successful development of new medical products, Dr. Gottlieb has testified as an expert witness on health and regulatory matters before the United States Senate and the House of Representatives. The Wall Street Journal identified him as a "forward thinker" on health policy and Congressional Quarterly as an "original thinker with a strong Libertarian streak."

In 2013 Dr. Gottlieb was appointed by the Senate Majority Leader to serve on the Federal Health Information Technology Policy Committee. Dr. Gottlieb is a member of the policy boards of the Society of Hospitalist Medicine and the Leukemia & Lymphoma Society. He is a Board Director to CombiMatrix (CMBX); MedaVante; American Pathology Partners; and Aptiv Solutions. He was previously a director to Bravo Health and Molecular Insight Pharmaceuticals (MIPI).

Dr. Gottlieb is a Clinical Assistant Professor at the New York University School of Medicine in Manhattan. He completed a residency in internal medicine at the Mount Sinai Hospital in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.